BRAF Mutation in Papillary Thyroid Cancer: Pathogenic Role, Molecular Bases, and Clinical ImplicationsMingzhao Xing|Endocrine Reviews|2007Cited by 986
Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancerRengyun Liu, Mingzhao Xing|Nature Communications|2018Cited by 179
BRAF V600E Maintains Proliferation, Transformation, and Tumorigenicity of BRAF-Mutant Papillary Thyroid Cancer CellsDingxie Liu, Mingzhao Xing|The Journal of Clinical Endocrinology & Metabolism|2007Cited by 124
The Akt-Specific Inhibitor MK2206 Selectively Inhibits Thyroid Cancer Cells Harboring Mutations That Can Activate the PI3K/Akt PathwayRuixin Liu, Mingzhao Xing|The Journal of Clinical Endocrinology & Metabolism|2011Cited by 105